Identification of a blood-based biomarker panel for classification of Alzheimer's disease

被引:56
作者
Laske, Christoph [1 ]
Leyhe, Thomas [1 ,2 ]
Stransky, Elke [1 ]
Hoffmann, Nadine [1 ]
Fallgatter, Andreas J. [1 ]
Dietzsch, Janko [3 ,4 ]
机构
[1] Univ Tubingen, Dept Psychiat & Psychotherapy, D-72076 Tubingen, Germany
[2] Univ Tubingen, Geriatr Ctr, D-72076 Tubingen, Germany
[3] Univ Tubingen, Ctr Bioinformat, Dept Informat & Cognit Sci, D-72076 Tubingen, Germany
[4] Univ Tubingen, Ctr Ophthalmol, Inst Ophthalm Res, D-72076 Tubingen, Germany
关键词
Alzheimer's disease; biomarker; blood; diagnostic test; support vector machine; DECREASED PLASMA; BRAIN-BARRIER; CSF; MECHANISMS; DEMENTIA; CORTISOL; SUPPORT; SERUM; LDL;
D O I
10.1017/S1461145711000459
中图分类号
R74 [神经病学与精神病学];
学科分类号
100204 [神经病学];
摘要
An ideal diagnostic test for Alzheimer's disease (AD) should be non-invasive and easily applicable. Thus, there is a clear need to search for biomarkers in blood. In the present study, we have used multivariate data analysis [support vector machine (SVM)] to investigate whether a blood-based biomarker panel allows discrimination between AD patients and healthy controls at the individual level. We collected a total of 155 serum samples from individuals with early AD and age-matched healthy controls and measured serum levels of 24 markers involved in several biological pathways by ELISA. The dataset was randomly split into a training set for predictor discovery and classification training and a test set for class prediction of blinded samples (3:1 ratio) to evaluate the chosen predictors and parameters. After selection of a feature group of the three most discriminative parameters (cortisol, von Willebrand factor, oxidized LDL antibodies) in the training set, the application of SVM to the training/independent test dataset resulted in an 81.7%/87.1% correct classification for AD and control subjects. In conclusion, we identified a panel of three blood markers, which allowed SVM-based distinguishing of AD patients from healthy controls on a single-subject classification level with clinically relevant accuracy and validity. Blood-based biomarkers might have utility in AD diagnostics as screening tool before further classification with CSF biomarkers and imaging. Future studies should examine whether blood-based biomarkers may also be useful to differentiate AD patients from other dementias.
引用
收藏
页码:1147 / 1155
页数:9
相关论文
共 35 条
[31]
Vapnik V., 1998, Statistical Learning Theory, P5
[32]
Verleysen M, 2005, LECT NOTES COMPUT SC, V3512, P758
[33]
Witten I. H., 2005, DATA MINING, V2, P403
[34]
Microvascular injury and blood-brain barrier leakage in Alzheimer's disease [J].
Zipser, B. D. ;
Johanson, C. E. ;
Gonzalez, L. ;
Berzin, T. M. ;
Tavares, R. ;
Hulette, C. M. ;
Vitek, M. P. ;
Hovanesian, V. ;
Stopa, E. G. .
NEUROBIOLOGY OF AGING, 2007, 28 (07) :977-986
[35]
Neurovascular mechanisms of Alzheimer's neurodegeneration [J].
Zlokovic, BV .
TRENDS IN NEUROSCIENCES, 2005, 28 (04) :202-208